Product
HS-10234
1 clinical trial
1 indication
Indication
Chronic Hepatitis B InfectionClinical trial
A Phase 3, Randomized, Multicenter, Double-blind, Double-dummy, Parallel-controlled Study to Evaluate the Safety and Efficacy of HS-10234 25 mg QD Versus TDF 300 mg QD for the Treatment of Patients With HBeAg+/- Chronic HBV Infection.Status: Active (not recruiting), Estimated PCD: 2020-05-31